Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 5 | BMC Cardiovascular Disorders

Fig. 5

From: Combining genetic proxies of drug targets and time-to-event analyses from longitudinal observational data to identify target patient populations

Fig. 5

Effect of ACE rs4968782 on time to cardiovascular (CV) death/heart transplant from first atrial fibrillation (AF) diagnosis in (a) unmatched and (b) matched individuals of European ancestry, and time to heart failure (HF) rehospitalization or CV death/heart transplant in (c) unmatched and (d) matched participants of any continental ancestry. Carriers of GA or AA genotype showed better survival for rehospitalization and severe cardiovascular outcome compared to individuals with GG genotype

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us